PRPH - ProPhase Labs, Inc.
0.3626
-0.085 -23.414%
Share volume: 5,493,740
Last Updated: 01-02-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.72%
PREVIOUS CLOSE
CHG
CHG%
$0.45
-0.08
-0.19%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-10-2024 | 08-14-2024 | 11-13-2024 | 05-20-2025 | 08-13-2025 | 11-19-2025 | |
| Total revenue | 3.634 M | 2.474 M | 3.146 M | 1.431 M | 1.247 M | 883.000 K | |
| Cost of revenue | 4.067 M | 2.950 M | 3.311 M | 905.000 K | 513.000 K | 1.006 M | |
| Gross profit | -433.000 K | -476.000 K | -165.000 K | 526.000 K | 734.000 K | -123.000 K | |
| -9.93% | 65.34% | 418.79% | 39.54% | -116.76% | |||
| Operating expenses | 7.865 M | 7.351 M | 7.772 M | 4.189 M | 4.628 M | 4.641 M | |
| Selling general and admin | 7.593 M | 7.212 M | 7.650 M | 4.092 M | 4.624 M | 4.635 M | |
| Research and development | 272.000 K | 139.000 K | 122.000 K | 97.000 K | 4.000 K | 6.000 K | |
| Total expenses | 7.865 M | 7.351 M | 7.772 M | 4.189 M | 4.628 M | 4.641 M | |
| -6.54% | 5.73% | -46.10% | 10.48% | 0.28% | |||
| Operating income | -8.298 M | -7.827 M | -7.937 M | -3.663 M | -3.894 M | -4.764 M | |
| Ebit | -8.316 M | -7.797 M | -7.937 M | -3.708 M | -4.757 M | -5.567 M | |
| Pretax income | -8.831 M | -8.440 M | -9.095 M | -4.678 M | -3.693 M | -6.996 M | |
| -4.43% | 7.76% | -48.57% | -21.06% | 89.44% | |||
| Income tax | -2.566 M | -2.287 M | -2.508 M | 0.000 | 779.000 K | -157.000 K | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -6.265 M | -6.153 M | -6.587 M | 3.966 M | -4.472 M | -6.839 M | |
| 1.79% | -7.05% | 160.21% | -212.76% | -52.93% |